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Background/aim: Solid organ transplant (SOT) recipients have increased risk of tuberculosis (TB). We aimed to investigate the
prevalence and features of TB in liver transplant (LT) recipients at our transplantation canter.
Materials and methods: All patients who underwent LT between January 2004 and December 2013 and whose data were accessible
were included in the study. Demographic features, tuberculin skin test (TST) results, and TB prevalence were recorded. Characteristics
of LT recipients who developed TB were evaluated.
Results: A total of 403 patients underwent LT during this period. Mean age was 47.27 ± 11.04 years; 280 (69.47%) were males. The TST
was administered to 108 (25.91%) and the QuantiFERON-TB test to 1 patient. TST positivity was determined in 28 (25.93%). Latent
TB infection (LTBI) treatment was not recommended to any of the LT candidates. In the posttransplant period, 5 patients (1.24%)
developed TB over a median duration of 14 (min: 7, max: 84) months, 2 of whom were found to have had LTBI in the pretransplant
period.
Conclusion: The prevalence of TB in LT recipients at our center was similar to that in the current literature. LTBI screening, including
risk factor assessment and TST/QuantiFERON-TB testing, is necessary in the early diagnostic workup for TB in LT recipients.
Key words: Tuberculosis, liver transplantation, immune suppression, latent tuberculosis infection

1. Introduction
Active tuberculosis (TB) may develop in a minority of individuals whose immune systems fail to evolve adequate
responses towards the Mycobacterium tuberculosis complex (1). Therefore, immunocompromised patients such as
solid organ transplant (SOT) recipients possess increased
risk for tuberculosis (TB), depending on the burden of the
disease in their country of residence (2). The prevalence
of TB in SOT recipients has been reported to be between
0.26% and 6.4% (3–6) in different settings, while in highburden areas prevalence of up to 15% has been defined
(7). Although the TB incidence rate has been decreasing in
Turkey (22 per 100,000 population for 2012), it is higher
than that of low-burden countries (7). TB prevalence in
SOT recipients has been reported to be between 1.9% and
6.7% in our country in a few studies (8–10).
Posttransplant TB development risk depends not only
on TB incidence in the population, but also on the number
of transplantations performed in the center, prior TB in-

fection or latent TB infection (LTBI) treatment in the pretransplant period, pretransplant tuberculin skin test (TST)
results, and the recipient’s age (1). Atypical presentations,
delayed diagnosis, and drug interactions lead to high TBrelated morbidity and mortality in SOT recipients (11).
Therefore, we aimed to investigate clinical characteristics
as well as risk factors associated with TB in liver transplant
(LT) recipients and posttransplant TB prevalence in a tertiary teaching hospital located in a TB low-burden city in
Turkey.
2. Materials and methods
We conducted a retrospective descriptive study and reviewed the data of LT recipients at our LT center for the
10-year period between January 2004 and December 2013.
Our local ethics committee approved the study (4 September 2014, 2014/28-13).
Pulmonologists, infection diseases specialists, psychiatrists, anesthesiologists, and gastroenterologists had
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evaluated all patients routinely for their own specific risk
factors prior to transplantation. Medical records obtained
by pulmonology consultations, including pretransplant
medical history, smoking status, previous TB contact, and
Bacillus Calmette–Guérin (BCG) vaccination, were investigated. Radiological findings associated with LTBI (apical
fibronodular lesions, calcified solitary nodules, calcified
lymph nodes, or pleural thickening) and TST results were
also recorded.
LT recipients who developed TB in the posttransplant
period were identified and posttransplant TB prevalence
was calculated. TB diagnosis in these patients depended
on symptoms, signs, and radiological findings (cavities,
consolidation, bronchopneumonia, lymphadenopathy)
compatible with active TB infection, in addition to microbiological (demonstration of acid-fast bacilli or culture
positivity of M. tuberculosis in specimens) and/or pathological (caseating granuloma) confirmation.
2.1. Immunosuppressive treatment
Tacrolimus, mycophenolate mofetil, and corticosteroids
were the immunosuppressive drugs administered in the
posttransplant period. Within a 20-day period, the drug
doses were tapered.
2.2. Statistical analysis
Data were analyzed with SPSS 15.0 (SPSS Inc., Chicago,
IL, USA). Mean and standard deviation or median and
minimum maximum values were expressed according
to the distribution of the data. Variables were compared
by Mann–Whitney U test for nonparametric values. Categorical data were evaluated by chi-square or Fisher’s exact
test. The relationship between independent variables was
evaluated by Spearman correlation analysis. P < 0.05 was
considered significant.
3. Results
Four hundred and three LTs were performed during the
given period. Demographic and clinical features of the
patients are shown in Table 1. The factors associated with
likelihood of TB development—previous TB history, contact with an active TB patient, and smoking—were asked
about for 214 (53.10%), 211 (52.35%), and 212 (52.61%) of
the patients, respectively. BCG vaccination was recorded
in 19 (8.81%) cases. Respiratory system physical examination was normal in 369 (91.57%). Chest X-ray was normal in 182 (84.7%) out of 215 interpretable radiographies.
Pathological radiographic appearances included consolidation, pleural effusion, mass, fibrotic lesions, and nodules. One hundred and eight (26.79%) patients underwent
the TST, and 28/103 (25.93%) were positive. Only one of
the patients had the QuantiFERON-TB test, which was
positive. The TST was applied to 3 of the patients who de-

Table 1. Characteristics of liver transplant recipients.
Characteristics

n (%)

Sex

280 (69.47)
123 (30.52)

Male
Female

Child classification (n = 379)

Donation type (n = 399)
Etiology

Child A 41 (10.81)
Child B 186 (49.07)
Child C 152 (40.10)

Living donor
Cadaveric

Hepatitis B
Hepatitis C
Cryptogenic
Other

227 (56.89)
172 (43.11)
88 (21.83)
36 (8.93)
32 (7.80)
247 (61.56)

Previous TB history (n = 214)

5 (2.33%)

Contact with active TB patient (n = 211)

5 (2.36%)

Smoking history (n = 212)

108 (50.94%)

Diabetes mellitus (n = 385)

76 (19.79%)

TST positivity (n = 108)

28 (25.93)
Mean ± SD

Age (years)

47.27 ± 11.04

MELD score

16.30 ± 6.54

TB, Tuberculosis; MELD score, Model for End-Stage Liver
Disease.

veloped posttransplant TB infection, and TST positivity
was obtained for one. TST median value was 7 (0–25) mm.
LTBI treatment was not administered in the pre- or posttransplant period to patients who had tested positive with
either the TST or QuantiFERON-TB.
The median duration of follow-up was 5 years in the
posttransplant period (min: 6 months, max: 10 years) until
2013. Following the transplant, 5 patients (1.24%) had active TB diagnoses, one of which was extrapulmonary. The
median duration of TB development after transplantation
was 14 months (7–84 months). Among these patients, TST
positivity was determined in one and QuantiFERON-TB
test positivity was also found in one. Characteristics of
these patients are shown in Table 2.
Age, body mass index (BMI), and Model for End-Stage
Liver Disease (MELD) scores of the TB patients were similar to those of other patients (P > 0.05).
4. Discussion
SOT recipients are prone to opportunistic infections due
to intense immunosuppression in the posttransplant period. Reactivation of LTBI is a challenging problem in
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Table 2. Characteristics of patients who developed active TB in the posttransplant period.
Case 1

Case 2

Case 3

Case 4

Case 5

Age–Sex

59–M

52–M

60–M

28–F

67–F

Primary disease

HBV, HCC

HBV, HCC

HBV

HBV, HDV

HCV

Donation type

Cadaveric

Living

Living

Living

Living

Posttransplant TB
development time

9th month

24th month

84th month

14th month

7th month

TST / QuantiFERON-TB
test

10 × 11 mm

20 × 23 mm

Not applied / +

Anergic /
not applied

Not applied

TB contact

-

-

+

-

-

Symptoms

-

Night sweats

Weight loss,
cough, sputum

Fatigue, cough,
fever

Fever, mouth
ulceration

Clinical signs

-

-

Crackles

Fever, crackles

Fever, mouth ulceration

Radiology

Fibrotic changes

Nodule

Nodule bronchiectasis Consolidation
cavity
atelectasis

Normal

HBV, Hepatitis B virus; HCC, hepatocellular carcinoma; HDV, hepatitis D virus; HCV, hepatitis C virus; TB, tuberculosis; TST, tuberculin
skin test.

posttransplant settings. Predictors and prevalence of TB
infection in SOT recipients have been investigated in different regions of the world, and a 20–74 times increased
risk with respect to the general population has been defined (3,12). In our study, a tertiary hospital experience for
LT recipients revealed risk factors for LTBI in 2 out of 5 TB
diagnosed patients and a TB prevalence similar to that of
the current literature on LT recipients.
We found hepatitis B infection as the most common
etiology for LT in both patients with and without TB. In
other studies, hepatitis C was defined as the most common
etiology (13,14). The findings of our study were attributed
to the high prevalence of HBsAg positivity in our country
(15).
Pretransplant LTBI screening in SOT recipients is
strongly recommended in transplantation guidelines (1).
However, risk factors for LTBI, such as previous TB and
contact with an active TB patient, had only been evaluated
in approximately 50% of the patients in our cohort. This
was due to the lack of a multidisciplinary approach and
organization, as well as inappropriate systematic follow-up
of LT candidates. We recognize that pulmonologist evaluations and TB records were properly organized after the
year 2007.
The predictors of TB development in SOT recipients
are defined as follows: graft from a cadaveric donor, intense
immunosuppression, use of T cell-depleting antibodies,
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diabetes mellitus, increased age of the recipient, TST
positivity, and risk factors or evidence for LTBI (1,12,16).
In our study, living donor LT (59%) was more frequent
than cadaveric donation, and 80% of the TB-diagnosed
patients had living-donor grafts. This is compatible with
our country’s data. The absence of TST results for the
donors is one of the limitations of our study. Among other
risk factors for posttransplant TB development, we found
that one of the TB-diagnosed patients had close contact
with an active TB patient, one was older than 65, and 2 had
positive TST or QuantiFERON-TB results.
TST and/or interferon-gamma release assays (IGRAs)
are the recommended laboratory tests for LTBI screening.
However, false negative results due to underlying liver disease and/or immunosuppression and false positive results
associated with high prevalence and prior BCG vaccination limit the value of TST screening in SOT patients (17).
In these circumstances, radiological studies are recommended. Turkey is an intermediate-burden country and
BCG vaccination is routine in childhood; therefore, chest
X-rays were administered to all our patients, and most of
the radiographs that we could access in the database were
normal (84.71%).
After excluding active TB disease, positive immunologic test results should indicate treatment for LTBI (1).
In our study, the TST was positive in 28 (25.93%) of 108
patients to whom it was administered, and the QuantiF-
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ERON-TB was positive in the one patient who underwent
this test. We attributed the TST positivity rates to our
country profile. Considering prior BCG vaccination, the
QuantiFERON-TB test might be a better choice for SOT
recipients in our country. However, it is still a sophisticated and expensive diagnostic test. Among the 5 patients
who developed TB in the posttransplant period, only 1 of
them was positive for the TST. In some studies, TST positivity has not been defined as a risk factor for TB infection,
based on the fact that active TB develops in only 0.9% of
TST-positive patients (11). Only one of our TST-positive
patients developed TB in the posttransplant period.
Although it is strongly recommended, drug toxicity
and/or interactions restrict the administration of LTBI
treatment in LT candidates. Isoniazid (INH) for 6–9
months of duration is the recommended choice (1,18).
Although most of the studies investigating INH for LTBI
treatment in LT candidates reported that the drug was
safe, the practical implementation is controversial (13,18).
Sidhu et al. evaluated 200 of 461 SOT candidates in a TB
screening program during a 10-year period (18). Eleven
of the patients refused the treatment and most of the remaining patients (64.5%) completed the therapy, although
LT candidates or recipients were less compliant. Active TB
was not detected in any patients in either the treatment
or treatment-rejected groups during the follow-up period
(18). While there are expert opinions and recommendations for LTBI screening and treatment in SOT, national
LTBI screening programs for LT candidates are not defined in some countries. Therefore, some centers avoid
medication based on the hypothesis that the risks of LTBI
treatment might outweigh the benefits (12,19). We were
also of that opinion, so we did not recommend LTBI treatment in either the pre- or posttransplant periods; we also
considered the relatively low compliance rates of LT patients to LTBI treatment and the conflicting results about
drug safety. However, after we determined that 40% of our
TB patients had a positive TST or QuantiFERON-TB test,
we decided to review our practice of not recommending
LTBI treatment. Some authors recommend LTBI treatment in LT candidates only with compensated cirrhosis,
recent TST conversion, previous inadequately treated TB,
or exposure to active TB (20,21).
We identified 5 (1.24%) TB cases out of 403 LT recipients. The incidence of TB in SOT recipients has
been reported to be between 0.45% and 3.5% in Europe
(11,12,22,23). Our prevalence rate is relatively low, considering that Turkey is an intermediate-burden country.
Among the previously defined risk factors, 2 of the TBdiagnosed patients had positive TST/IGRA results and one

of them had a previous active TB contact; however, all had
normal radiograms in the pretransplant period. Only one
of our TB patients had extrapulmonary involvement. The
extrapulmonary TB rate was defined as 16% in one series,
which is higher than that for the general population (3,23).
TB infection generally occurs in the first year after transplantation, but a peak after 2 years has also been defined
(5,21). In our study, we found median duration of TB infection development after transplantation to be 14 months
(7–84 months). All transplant recipients except one presented in the first 2 years. Constitutional symptoms related
with TB including night sweats, weight loss, and fever are
common in TB patients with SOT (1). All of our TB patients had these symptoms (Table 2).
Diagnosis of TB in SOT recipients is similar to that
in immunocompetent patients with positive smears for
acid-fast bacilli and/or mycobacterial culture or histopathological confirmation. A pyrazinamide-free regimen
can be preferred in nonsevere hepatic disease; in severe
hepatic disease, a regimen that is both isoniazid- and
pyrazinamide-free is recommended (22). The doses of calcineurin inhibitors, mTOR, and corticosteroids should be
increased with a rifamycin-inclusive regimen. (24). Fluoroquinolones might be used as a first-line agent when a
standard regimen cannot be used (25). All of our patients
were treated with standard TB medication, except for one
to whom moxifloxacin instead of rifamycin was administered. One of our patients worsened during the course of
therapy; fever and lymph node enlargement developed.
This clinical deterioration was explained by immune reconstitution inflammatory syndrome and high-dose systemic corticosteroids were given. One of our patients died
in the first month of the treatment due to acute rejection.
Drug interactions between immunosuppressive and antituberculosis drugs might end with graft rejection, as in
our patient (20). A mortality rate of up to 40% has been
described in SOT recipients with TB (2,3,11,21).
We determined a relatively low prevalence of TB in the
LT recipients at our center, although only half of the recipients were evaluated for LTBI. This is due to suboptimal
recording and preoperative evaluation in the first years
of our center’s transplantation practice. Two of our TBdiagnosed patients had LTBI screening test positivity and
one stated a close contact with an active patient. Therefore, pretransplant LTBI screening should be performed,
and LTBI treatment might be offered in LT recipients with
stable disease after considering the risk/benefit ratio. Standard TB treatment was successfully administered to our
patients.
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